OSLO - 16th of January 2024: 

Reference is made to SoftOx (the Company) press release of 11th of January 2024
where the Company announced on-going work to restructure the financial
situation.
The Company is in process of reaching an agreement with the lenders in the NOK
40 million convertible loan with due date of 15th of January 2024 to prolong the
due date until 1st of April 2024 on certain conditions, proposed by one of the
largest holders in the loan. 
So far, 88% of the holders of the convertible loan have accepted the proposal.
The company will revert with further information after all lenders have given
their feedback. 

SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: (+47) 977 50 071 (Chairman of the Board Geir Almås)
About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Medtech and
clinical-stage pharmaceutical company based in Oslo, Norway, with the goal of
reducing
the spread of infection and emergence of antimicrobial resistance.
For more information on SoftOx, visit www.soft-ox.com

Click here for more information

© Oslo Bors ASA, source Oslo Stock Exchange